Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 23Lymphoma, Non-Hodgkin 19Hodgkin Disease 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Acute 7Lymphoma 6Myelodysplastic Syndromes 5Neoplasms, Plasma Cell 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 2Sarcoma, Myeloid 1Pancreatic Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Juvenile 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Children Cancer, Solid Tumor 1

Interventions

Rituximab 208Cyclophosphamide 167Etoposide 83Prednisone 79Vincristine 77Doxorubicin 76Peripheral Blood Stem Cell Transplantation 61Filgrastim 55Cytarabine 47fludarabine phosphate 46Radiotherapy 43Lenalidomide 41Mycophenolic Acid 40Tacrolimus 36Methotrexate 35Melphalan 35Busulfan 35Gemcitabine 32Carmustine 32Cyclosporine 31Whole-Body Irradiation 29Ifosfamide 28Antilymphocyte Serum 26zanubrutinib 25polatuzumab vedotin 25Dexamethasone 23Methylprednisolone 22ibritumomab tiuxetan 20Carboplatin 20Oxaliplatin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Large B-Cell, Diffuse × plerixafor × Clear all
NCT02570542 2025-11-26

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
59 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡